Blackstone Life Sciences Deal History & Licensing Activity
Blackstone Life Sciences is a life sciences. Over the past three years, Blackstone Life Sciences has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Antibodies
Focus Area
Gastroenterology
Blackstone Life Sciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Blackstone Life Sciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| duvakitug (TEV-574/SAR447189) | Teva | Antibodies | Phase 3 | collaboration | Jun 2025 |
Blackstone Life Sciences Pipeline Focus
Therapeutic areas and modalities where Blackstone Life Sciences is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Blackstone Life Sciences's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Gastroenterology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Blackstone Life Sciences Licensing & Deal Activity
Blackstone Life Sciences is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Blackstone Life Sciences ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Blackstone Life Sciences include Gastroenterology (2 deals and trials), and Infectious Disease (1 deal and trial). In terms of modality, Blackstone Life Sciences has shown particular interest in antibodies, mrna.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Blackstone Life Sciences and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Blackstone Life Sciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.